Literature DB >> 12111303

Sensory features of variant Creutzfeldt-Jakob disease.

M-A Macleod1, G E Stewart, M Zeidler, R Will, R Knight.   

Abstract

OBJECTIVE: Sensory symptoms are a prominent feature of variant Creutzfeldt-Jakob disease (vCJD), occurring at an early stage of the illness. They are persistent and can be troublesome. Here, they are described in detail and a possible anatomical basis is discussed.
METHODS: The first 50 cases of vCJD confirmed by the National CJD Surveillance Unit (NCJDSU) were reviewed. Where possible the patients and their relatives were interviewed and case notes were examined. The presence and nature of sensory symptoms and signs were noted. Results of investigation and types of treatment offered were also reviewed.
RESULTS: Of 50 definite cases, 64 % had persistent sensory symptoms, 16 % had no sensory symptoms and 18 % were uncertain. In 2 % there was insufficient information. Of the 32 with definite symptoms, 31 % were symptomatic from the onset of the illness. The symptoms were varied and some patients complained of more than one type of symptom. Limb pain was described in 63 % cases. This was the most common symptom and was often non-specific and poorly localised, usually occurring in the lower limbs. Other symptoms included cold feelings (25 % patients), dysaesthesia (28 % patients), paraesthesia (31 % patients) and numbness (25 % patients). The symptoms were lateralised in 31 % of patients.
CONCLUSIONS: Sensory symptoms are a prominent feature of vCJD, occurring in nearly two thirds of cases. They may help distinguish variant from sporadic CJD. They are likely to be of thalamic origin but the recognised MRI changes in vCJD do not correlate with the presence or absence of sensory symptoms. Neuropathological changes in the thalamus, however, show marked astrocytosis and neuronal loss.

Entities:  

Mesh:

Year:  2002        PMID: 12111303     DOI: 10.1007/s00415-002-0696-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

Review 1.  Long-term control of neuropathic pain in a non-viral gene therapy paradigm.

Authors:  E M Sloane; R G Soderquist; S F Maier; M J Mahoney; L R Watkins; E D Milligan
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

Review 2.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

3.  Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental Multiple Sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy.

Authors:  Evan Sloane; A Ledeboer; W Seibert; B Coats; M van Strien; S F Maier; K W Johnson; R Chavez; L R Watkins; L Leinwand; E D Milligan; A M Van Dam
Journal:  Brain Behav Immun       Date:  2008-09-20       Impact factor: 7.217

4.  Cellular prion protein protects from inflammatory and neuropathic pain.

Authors:  Vinicius M Gadotti; Gerald W Zamponi
Journal:  Mol Pain       Date:  2011-08-16       Impact factor: 3.395

5.  Prion diseases are undercompulsory notification in Brazil: Surveillance of cases evaluated by biochemicaland/or genetic markers from 2005 to 2007.

Authors:  Vilma Regina Martins; Hélio Rodrigues Gomes; Leila Chimelli; Sergio Rosemberg; Michele Christine Landemberger
Journal:  Dement Neuropsychol       Date:  2007 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.